Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy

Area of Science:

• Oncology
• Nanomedicine
• Pharmacology

Background:

• Oral tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) family are established treatments for human malignancies.
• Despite their targeted nature, EGFR-TKIs face challenges including low solubility, variable oral bioavailability, and the development of drug resistance.
• These limitations restrict the clinical application and efficacy of existing EGFR-TKIs.

Purpose of the Study:

• To review the advantages of utilizing nanocarriers for the delivery of EGFR-TKIs.
• To highlight how nanotechnology can overcome the pharmacokinetic and resistance limitations of traditional EGFR-TKI formulations.
• To explore advanced, non-oral delivery strategies for enhanced EGFR-TKI efficacy.

Main Methods:

• Literature review of current research on nanotechnology-based drug delivery systems for EGFR-TKIs.
• Analysis of studies focusing on nanocarrier formulations designed to improve drug solubility and bioavailability.
• Examination of data on the pharmacokinetic profiles and tissue-targeting capabilities of nanocarrier-delivered EGFR-TKIs.

Main Results:

• Nanotechnology offers significant improvements in the solubility and oral bioavailability of EGFR-TKIs.
• Nanocarrier systems demonstrate enhanced tissue-targeting abilities and improved pharmacokinetic profiles compared to conventional administration.
• Non-oral delivery routes utilizing nanocarriers can mitigate issues of drug resistance and reduce daily dosage requirements.

Conclusions:

• Nanocarriers represent a promising platform for optimizing the delivery and therapeutic efficacy of EGFR-TKIs.
• Nanotechnology-based strategies can effectively address the inherent limitations of EGFR-TKIs, leading to better patient outcomes.
• Further development of nanocarrier systems holds potential for advancing targeted cancer therapy.